Background: LKB1 is a serine/threonine kinase important for cell polarity and motility. Results: LKB1 loss causes focal adhesion kinase hyperactivation and aberrant cell motility. Conclusion: LKB1 represses focal adhesion kinase to regulate its turnover. Significance: This provides information on how LKB1 regulates the cell adhesion pathway during cell motility.
physiologic processes such as embryogenesis and wound healing, but it is also an integral characteristic in pathological conditions such as cancer metastasis (1) (2) (3) (4) (5) (6) (7) (8) . Cell motility itself has been studied in a variety of organisms to create a general model. First, cells polarize to establish a direction of movement and then generate actin-based lamellipodia (9) . Within the lamellipodia and surrounding region, motility proteins are targeted via microtubules and actin to regulate signaling events that control movement, directionality, and adhesion. The coordinated cycle of lamellipodia extension, formation of adhesion sites, site turnover, and translocation of the cell body are essential for directed cell movement (10) .
The dynamic regulation of adhesion signaling is important for proper cell motility to occur. Focal adhesion kinase (FAK) 2 acts as a signaling node at cell adhesion sites called focal contacts to promote cytoskeletal reorganization, adhesion, migration, and survival (11) . FAK regulates cell motility through integrins and growth factor receptors (11) by relaying cues from the extracellular matrix through the plasma membrane, and into the cytoplasm. A series of tyrosine phosphorylation events controls FAK activation whereby ligand binding to a FAK-associated integrin causes autophosphorylation of FAK at residue Tyr 397 (12) . This reveals a binding motif for SH2-domain-containing proteins such as Src, which further phosphorylates FAK at Tyr 861 , Tyr 925 , Tyr 576 , and Tyr 577 (13) (14) (15) (16) . Loss of cell polarity is one of the first events to trigger cell dedifferentiation, allowing cells to become more migratory (17) (18) (19) . One proposed master regulator of cell polarity is the serine/threonine kinase LKB1. LKB1 activation causes cell autonomous polarization even in the absence of junctional cellcell contacts (20) and several LKB1 mutants are incapable of polarizing normal epithelial cells (21) . LKB1 translocates to the cellular leading edge and associates with actin (22, 23) when cell migration is initiated to regulate active cdc42 (23) . In addition, LKB1 plays key roles in energy metabolism via the AMP-activated protein kinase-mammalian target of rapamycin pathway (24 -26) and the link between energy sensing and cell polarity is beginning to be unraveled (27, 28) . LKB1 activity is regulated by the pseudokinase STRAD␣ and the scaffolding protein MO25 through a phosphorylation-independent mechanism. STRAD␣ and MO25 promote the active conformation of LKB1, which is stabilized by MO25 interacting with the LKB1 activation loop (29, 30) . Cellular studies show that STRAD␣ influences LKB1 localization such that STRAD␣ drives LKB1 into the cytoplasm (20, 29, 31, 32) . LKB1 is also a lung cancer tumor suppressor protein and it ranks as the third most frequently mutated gene in lung adenocarcinoma after p53 and Ras (33) (34) (35) .
Genome-wide analyses of primary and metastatic de novo lung cancers with LKB1 loss show increased metastatic disease and a disruption in adhesion signaling (36, 37) . We build upon these findings to determine how LKB1 regulates FAK and to test the central hypothesis that LKB1 inactivation promotes aberrant cell migration through uncontrolled adhesion signaling. Our results show that LKB1 represses FAK activation whereby LKB1 (or STRAD␣) loss leads to FAK activation and causes a more exploratory behavior during cell migration. When present, LKB1 stabilizes focal adhesions at the leading edge of migratory cells to repress focal adhesion site turnover. We conclude that LKB1 serves as a FAK repressor, and when LKB1 is absent, aberrant FAK signaling ensues, resulting in rapid FAK site turnover and lack of directional persistence.
EXPERIMENTAL PROCEDURES
Cell Culture and Drug Treatment-H1299 or H157 human NSCLC cells (ATCC, Manassas, VA) were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 100 units/ml of penicillin/streptomycin, and maintained at 37°C and 5% CO 2 . Stable pLKO.1 vector control, LKB1-shRNA, and STRAD-shRNA H1299 cells were created by lentiviral infection using specific shRNA constructs from Open Biosystems (Rockford, IL) as described (38) . Unless otherwise noted, cells were plated onto tissue culture plates or slides coated with 5 g/cm 2 of human fibronectin (Chemicon/Millipore, Billerica, MA) according to the manufacturer's instructions. For drug treatment studies, cells were treated with either DMSO vehicle or the indicated concentration of the FAK inhibitor PF-573228 (Sigma).
Antibodies and siRNAs-Antibodies against FAK-Tyr(P) 397 , FAK-Tyr(P) 861 (Invitrogen), total FAK (BD Biosciences, Franklin Lakes, NJ), STRAD N-13 (Santa Cruz Biotechnology, Santa Cruz, CA), LKB1, FLAG M2 and GFP (Sigma), and GAPDH (Cell Signaling, Beverly, MA) were used for Western blotting, immunofluorescence, and immunoprecipitation assays. The first LKB1 siRNA sequence used was GGACUGACGUGUA-GAACAATT and the second from Sigma (catalog number SIHK2135). siRNA to FAK was from a Dharmacon Smart Pool, catalog number L-003164-00-0005.
Cell Adhesion Assay-For cell adhesion studies, all cell lines were trypsinized concurrently, neutralized, and re-suspended in normal growth media at 3.0 ϫ 10 5 cells/ml. Using a multichannel pipette, 100 l of cell suspension were added to individual wells of a 96-well plate. At 0, 10, 20, 40, 60, and 80 min post-seeding, the contents of the respective wells were aspirated. The wells were then washed carefully with PBS twice and fresh growth media was added to allow for normal cell growth and attachment to occur until the last time point was reached. After 80 min, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Invitrogen) was performed according to the manufacturer's protocol to quantitate the number of attached cells. Individual time points were plated in triplicate for each cell line and the data from three separate assays were combined to determine relative cell adhesion.
Transfections and Western Blot-Transient siRNA transfections were performed using Oligofectamine (Invitrogen) and 200 nM scrambled control, LKB1-, STRAD-, or FAK-specific siRNA oligos (Qiagen, Valencia, CA) according to the manufacturer's protocol. FLAG-LKB1 truncates in the pcDNA3 vector were generated by the Emory University Custom Cloning Core Facility. For overexpression experiments, cells were transfected with pcDNA3-GFP, FAK-GFP (generous gift from Dr. Gregg Gundersen), or pCDNA3 FLAG-LKB1 truncates using TransIt-LT1 transfection reagent (Mirus, Madison, WI) according to the manufacturer's protocol. Cells were harvested and lysed in TNES buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% Igepal) supplemented with Roche Complete Protease Inhibitor and/or Pierce Halt Phosphatase Inhibitor Mixture per the manufacturer's instructions. Protein concentrations were determined by the bicinchoninic acid protein (BCA) assay kit (Pierce). Equal concentrations of lysates were boiled in Laemmli sample buffer, loaded onto SDS-10% polyacrylamide gels, transferred onto PVDF membranes, blocked in 10% nonfat dried milk for 1 h at room temperature, probed overnight at 4°C with primary antibodies diluted in either 5% BSA or nonfat dried milk, followed by appropriate horseradish peroxidase-conjugated secondary antibody and visualized via chemiluminescence.
Confocal Microscopy and Image Analysis-Fixed-cell immunofluorescence was performed as described previously (39, 40) . Antibodies for immunofluorescence experiments were the same as used above with the addition of conjugated Alexa Fluor 647 phalloidin (Invitrogen) to image actin, and were incubated with fixed cells at 4°C overnight. Alexa Fluor 488, 563, or 633 secondary antibodies (Invitrogen) were used at a dilution of 1:500 and were incubated for 1 h at room temperature. Nuclear staining was performed by incubating cells with 0.4 mol/liter of 4Ј,6-diamidino-2-phenylindole (DAPI) for 10 min prior to mounting the coverslips. Fixed cells were imaged on a Zeiss LSM 510 META as described previously. Either a ϫ63 or ϫ100 Zeiss Plan-Apo oil objective was used (NA of 1.3 and 1.4, respectively) for imaging. Fluorescence intensity was quantified using the Zeiss LSM 510 software.
Live cell imaging of motile cells was performed using a PerkinElmer Life Sciences Ultraview ERS spinning disc confocal (CSU21) microscope similar to that previously described (41, 42) . The confocal unit is mounted onto a Zeiss Axiovert (Thornwood, NY) microscope encased at 37°C with 5% humidified CO 2 . For transmitted light images of single cell motility (Figs. 3 and 4 ), images were acquired using a ϫ10 Plan Neofluar objective (NA ϭ 0.3) every 10 min over the course of 16 -24 h. For fluorescence confocal images of GFP-FAK sites (Fig. 5) , Z-stacks of single cells were acquired every 2 min for up to 2 h using a Zeiss Plan-Apo ϫ100 oil objective (NA 1.4) on the spin-ning disc confocal. Exposure times using a Hamamatsu Orca ER CCD camera ranged from 300 to 600 ms with 2X2 binning.
Image analysis of single cell motility (Figs. 3 and 4) was performed using the manual tracking feature in Volocity software (5.5.2) to generate migration plots, meandering indices, and cell velocity measurements. Cells were plated onto glass bottom chamber slides at ϳ30 -40% confluence and movement was tracked by taking images every 10 min for 12 h. In cases where GFP was used, cells were transfected 48 h prior to imaging and images were acquired using the 488-nm line with standard GFP emission filter sets. For meandering index and cell velocity analyses, at least 25 individual cells were tracked over the course of three separate experiments.
Image analysis of individual FAK sites in fixed cells ( Fig. 1 ) was performed using Zeiss LSM software and ImageJ. A line profile was created through the leading edge of the cell to generate intensity profiles. From these intensity profiles the peaks were used to determine the peak fluorescence intensity and the site widths were calculated based upon the distance between the two troughs. Image analysis of Tyr(P)-FAK intensity at leading edge regions that contain LKB1 compared with regions that do not were performed in Metamorph. To do this, regions containing LKB1 were defined by thresholding for the LKB1 signal at the leading edge then creating a region of interest (ROI) around this threshold. This ROI was then transferred to the Tyr(P)-FAK image and the mean Tyr(P)-FAK intensity was calculated for this ROI. A mean Tyr(P)-FAK intensity was also created for regions not containing LKB1 staining (i.e. below the LKB1 image threshold). For each molecular marker, acquisition settings were kept the same throughout the experiment.
Image analysis of individual FAK sites from live cell confocal images ( Fig. 6 ) was performed in Volocity (PerkinElmer Life Sciences) software. A ROI was drawn around a Z-stack of a single lamellipodia and the image was cropped around the ROI. The images were then thresholded and the smoothing filter was used. Automatic detection of objects was employed and objects less than a volume of 1000 m 3 were excluded from the analysis. The ability of the software to automatically identify the object over time was confirmed and automated analysis of the FAK site volume over time was performed. These raw data were then used to determine FAK site duration and change in size. All statistical analysis was done either using GraphPad or Microsoft Excel. Densitometry of the Western blot ( Fig. 5C ) was done by measuring the mean gray intensity of Tyr(P) 397 -FAK and total FAK bands. Tyr(P) 397 -FAK was normalized to total FAK by creating a Tyr(P) 397 -FAK/total FAK ratio.
Co-immunoprecipitation Experiments and in Vitro Binding
Assay-For co-immunoprecipitation (co-IP) studies, cells were lysed at ϳ75% confluence in lysis buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 5 mM EDTA, 5% glycerol, 1% Triton X-100, 25 mM NaF, 2 mM Na 2 VO 4 , 20 mM sodium molybdate) supplemented with 1ϫ complete protease inhibitor mixture (Roche Applied Science). Lysates were incubated on ice for 30 min, centrifuged at 14,000 ϫ g for 15 min at 4°C, and supernatants were collected. The BCA assay was used to quantitate the protein concentration with 50 g of lysate added to Laemmli sample buffer for total input Western blots and 750 g of lysate in 500 l of lysis buffer for co-IP experiments. Diluted lysates were rotated with 10 g of normal mouse IgG (Millipore, Billerica, MA), normal rabbit IgG, mouse anti-human LKB1 (Sigma), or rabbit anti-human FAK antibody (Invitrogen) overnight at 4°C. For each sample, 50 l of Dynabeads IgG (Invitrogen) were resuspended in wash buffer (Tris-buffered saline supplemented with protease and phosphatase inhibitors) and added to the lysateantibody suspension for 2 h at 4°C. Co-immunoprecipitated complexes were collected using the Dynabead magnet and washed 4 times with 500 l of wash buffer for 30 min each at 4°C. After the final wash, complexes were re-suspended in 100 l of wash buffer, transferred to fresh tubes, aspirated, and beads were incubated with 50 l of Laemmli sample buffer for 10 min before loading onto a 10% PAGE gel.
For in vitro binding assays, 1 g of purified LKB1/STRAD/ MO25␣ (Millipore number 14-596) and FAK (Invitrogen number PV3832) were incubated together and separately at 4°C for 2 h in 500 l of IP buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 5% glycerol, 0.1% Triton X-100, 25 mM NaF, 2 mM Na 2 VO 4 , 20 mM sodium molybdate) supplemented with 1ϫ complete protease inhibitor mixture (Sigma S8820). 50 l of Dynabeads-Protein G (Invitrogen) were incubated with either FAK (Life technologies AHO0502) or LKB1 (Santa Cruz sc-32245) antibody. For each sample, 50 l of Dynabeads-Protein G (Invitrogen) were re-suspended in IP buffer and samples were added and gently mixed for 2 h at 4°C. Protein complexes were collected according to protocol. After the final wash, beads were incubated with 60 l of 2ϫ Laemmli sample buffer for 10 min at 95°C before loading onto a 10% PAGE gel.
Cell Viability Assay-Cell viability was determined by performing the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay after 72 h drug treatment according to the manufacturer's protocol. Absorbance was read on the Epoch plate reader (BioTek Instruments, Winooski, VT).
RESULTS

Loss of LKB1 Activity Enhances Cell Adhesion and FAK
Activation-H1299 non-small cell lung cancer cells were created that are deficient in either LKB1 or the LKB1 binding partner STRAD␣ (shLKB1 and shSTRAD, respectively). These cell lines were compared with their isogenic parental vector control cell line pLKO.1. Stable knockdown of either LKB1 or STRAD␣ increased phosphorylation of FAK at two of its activating residues, Tyr 397 and Tyr 861 (Fig. 1A) . Total FAK levels were unchanged in all cases and as previously reported, LKB1 depletion also reduced STRAD␣ protein levels (43) . This result was confirmed using two additional siRNAs in H1299 cells (data not shown). Additionally, we showed by confocal microscopy that fluorescence intensities of both FAK-Tyr(P) 397 and Tyr(P) 861 were elevated at the leading edge of migrating shLKB1 cells compared with parental pLKO.1 cells using quantitative image analysis (Fig. 1, B and C) . Representative examples and bar graphs show that shLKB1 and shSTRAD cells had a greater number of and more intense Tyr(P)-FAK sites with reduced width, compared with control pLKO.1 cells (Fig. 1, B and C) . In contrast, there was no observed difference in Tyr(P) 118 -Paxillin intensity or localization between pLKO.1 and shLKB1 cells (data not shown). The increase in FAK phosphorylation in LKB1-compromised cells was associated with a concomitant enhancement in cell adhesion to a fibronectin substrate (Fig.  1D) . After 80 min, adhesion was 51% greater in shLKB1 cells and 44% greater in shSTRAD cells compared with pLKO.1 cells.
To investigate the relationship between LKB1 and FAK, co-IP experiments were performed in H1299 pLKO.1 cells. Pull-down with an LKB1 antibody co-IPs endogenous FAK and conversely pull down with a total FAK antibody co-IPs endogenous LKB1 (Fig. 2A) . Specificity for this interaction was confirmed by the inability of matched isotype IgG antibodies to pull down the respective proteins. Total lysate input showed similar levels for both LKB1 and FAK. A direct interaction between purified LKB1-STRAD-MO25 and FAK was tested using an in vitro binding assay. In this case, the IP for purified FAK did not pull down LKB1, and the IP for LKB1 did not pull down FAK (Fig. 2B) . Therefore, this result shows that purified FAK and LKB1 do not directly interact in vitro but instead form an in vivo complex.
Because LKB1 loss drives FAK-Tyr(P) 397 , we propose that LKB1 serves as a FAK repressor. If this is the case, then we would expect that when LKB1 is present, FAK remains inactive (i.e. not phosphorylated), but when LKB1 is absent FAK can be phosphorylated. To test this model, we investigated the association of LKB1 with Tyr(P)-FAK in motile lung cancer cells to determine whether the presence of LKB1 represses FAK phosphorylation. H1299 pLKO.1 cells were plated to confluence, and migration was stimulated using a wounding model. Subcellular localizations of LKB1 and phospho-FAK (Tyr  397 and  Tyr  861 ) at an early (20 min) and late (60 min) time point postmotility stimulus were analyzed at the leading edge of motile cells (Fig. 2C) . As previously shown, LKB1 co-localized with actin at the leading edge (23); however, differences in subcellular distributions of LKB1 and Tyr(P)-FAK were observed between the early and late time points. At 20 min post-wounding, LKB1 existed in close proximity to both Tyr(P) 397 -FAK (Fig. 2C ) and Tyr(P) 861 -FAK (Fig. 2D) . After 60 min post-motility stimulus, LKB1 and Tyr(P) 397 -FAK showed a stark shift in localization with LKB1 and Tyr(P) 397 -FAK residing in mutually exclusive regions of the leading edge of lamellipodia. This contrast in leading edge localization was also observed between LKB1 and Tyr(P) 861 -FAK (Fig. 2D) . These results were quantitated by measuring the Tyr(P)-FAK signal in leading edge regions where LKB1 is present compared with regions where LKB1 is absent (Fig. 2E ) and show that regions without LKB1 have a greater Tyr(P) 397 -FAK and Tyr(P) 861 -FAK fluorescent intensity compared with regions with LKB1 (Fig. 2E) . Thus, LKB1 is excluded from Tyr(P)-FAK sites at later time points at the leading edge of motile cells.
LKB1-compromised Cells Exhibit Impaired Directional Persistence, Which Is Restored
Upon FAK Inhibition-Because loss of either LKB1 or STRAD␣ enhances cell adhesion and causes FAK hyperactivation, we wanted to determine how cell movement was affected by loss of either LKB1 or STRAD␣. Cells were plated on fibronectin at ϳ30 -40% confluence and individual cell tracking was analyzed by live-cell microscopy (example in supplemental Movie S1). Representative tracings (Fig.  3A) and cumulative cell migration plots (Fig. 3B) demonstrate that pLKO.1 cell migration paths were relatively straight and directional compared with the LKB1-compromised cells (i.e. shLKB1 and shSTRAD), which were more circuitous and lacked directional persistence. Directionality was quantified by determining the meandering index, which is the ratio of the displacement to the path length. A value closer to 1 indicates complete linear directionality, whereas a value closer to 0 indicates a lack of directionality and directional persistence. Using this method, control pLKO.1 cells had a meandering index of 0.429 Ϯ 0.019 compared with shLKB1 and shSTRAD cells, which had significantly lower indices of 0.279 Ϯ 0.017 and 0.248 Ϯ 0.018, respectively (Fig. 3E ).
Next, we tested the hypothesis that subsequent pharmacological inhibition of FAK can restore normal directional persistence in LKB1-depleted cells. To do this, cells were treated with the FAK inhibitor PF-573228. All cell lines displayed similar sensitivity to PF-573228 with 72 h cytotoxic IC 50 values of ϳ10 M (data not shown). PF-573228 inhibited Tyr(P) 397 -FAK as low as 0.5 M, but inhibition of Tyr(P) 861 -FAK was not observed to 10 M (Fig. 3A) . Furthermore, treatment inhibited cell adhesion more potently in shLKB1 cells compared with control pLKO.1 cells (Fig. 3B) . Immunofluorescence confocal images show intracellular inhibition of Tyr(P) 397 -FAK in control, shLKB1, and shSTRAD cells (Fig. 3C) . Representative tracings (Fig. 3D ) and cumulative cell migration plots (Fig. 3E ) using 0.5 M PF-573228 show that pharmacological FAK inhibition restored normal directionality in shLKB1 and shSTRAD cells as their paths of migration were elongated and more directional. Meandering indices (Fig. 3F) (Fig. 3F) . Additionally, PF-573228 decreased individual cell velocity in LKB1-compromised cells (Fig. 3G) .
To further test if aberrant directionality and lack of directional persistence in shLKB1 and shSTRAD cells is due to hyperactivated FAK, cells were transfected with FAK-specific siRNA to deplete total FAK levels (Fig. 4A) . Cell migration plots (Fig. 4B ) and meandering index analyses (Fig. 4C) show that knockdown of FAK in the LKB1-compromised cell lines significantly restored directionality, analogous to PF-573228 treatment. FAK siRNA transfection did not improve directionality in pLKO.1 cells, but did increase meandering indices by ϳ38 and 33% in shLKB1 and shSTRAD cells, respectively. Similar to PF-573228 treatment, FAK siRNA transfection decreased individual cell velocity in LKB1-compromised cells (Fig. 4D) .
LKB1 Re-expression Suppresses FAK and the LKB1 C-terminal and Kinase Domains Are Not Required for LKB1 to Repress Tyr(P)
397 -FAK-We show that LKB1 associates with FAK and mediates the directional persistence via FAK. We next wanted to determine which regions of LKB1 can repress Tyr(P) 397 -FAK and rescue meandering defects using FLAG-LKB1 truncates (Fig. 5A) . LKB1 truncates were separately expressed in H157 cells (LKB1 null) and Tyr(P) 397 -FAK levels were assessed by Western blotting (Fig. 5B) ; however, the LKB1 N-terminal domain (NTD) could not be detected on the blot likely due to its size but was detected using FLAG immunofluorescence (Fig.  5C ). Additional optical sections of the FLAG LKB1 wild-type and LKB1 NTD show localization to the nucleus as well (data not shown). Expression of full-length LKB1 repressed Tyr(P) 397 -FAK levels (Fig. 5D) , which would be consistent with LKB1 acting as a FAK repressor. Either the LKB1 kinase (48 -309) or C-terminal domain (310 -433) alone or together (48 -433) could not suppress FAK. In contrast, both the LKB1 NTDonly (FLAG-LKB1-(1-47)) and the LKB1 NTD plus kinase domain (FLAG LKB1-(1-309)) were capable of repressing Tyr(P) 397 -FAK. The truncate lacking the kinase domain (i.e. Nand C-terminal domains fused; FLAG-LKB1 ⌬48 -309) was incapable of restoring normal Tyr(P) 397 -FAK levels (Fig. 5D ). Densitometry results of the FAK repression assay confirm these observations (Fig. 5D) . Taken together, these data show that wild-type LKB1 re-expression suppresses FAK and the LKB1 C-terminal and kinase domains are not required for LKB1 to repress Tyr(P) 397 -FAK. Furthermore, these data suggest that it is the LKB1 NTD that is critical for repressing FAK, however, additional studies are needed to confirm this finding.
We performed a complementary experiment to test if the LKB1 NTD also increases the meandering index (i.e. greater directional persistence) in H157 LKB1 null cells. The data showed that control GFP-transfected cells had a mean meandering index of 0.2096 Ϯ 0.1425 (n ϭ 96 cells); however, upon transfection of the LKB1 NTD-only (amino acids 1-47), the meandering index significantly increased to 0.5606 Ϯ 0.2055 (n ϭ 31; p Ͻ 0.0001; Fig. 5E ). Transfection of two other NTD containing plasmids, wild-type GFP:LKB1 and GFP:NTD ϩ KD (amino acids 1-309) also increased the meandering index. In contrast, transfection with the LKB1 CTD-only (amino acids 310 -433), LKB1 KD only, or plasmids containing both, did not lead to an increase in the meandering index (Fig. 5D) . Furthermore, neither the LKB1 NTD nor CTD only plasmids led to any changes in cell velocity (Fig. 5E) but plasmids containing the kinase domain (GFP:LKB1 wild-type, KD only, and CTD ϩ KD) did decrease velocity. These data show that the LKB1 NTD can increase the meandering index, and hence the directional persistence of cells, whereas the LKB1 kinase domain may impact cellular velocity.
LKB1 Depletion Causes Rapid Focal Adhesion Site TurnoverTo determine whether LKB1 loss impacts FAK dynamics, pLKO.1 and shLKB1 cells were transfected with a GFP-FAK plasmid, and cells were imaged by live-cell confocal microscopy. GFP-FAK assembled into adhesion site structures (Fig.  6A , supplemental Movie S2) at the cell membrane similar to that observed by immunofluorescence for endogenous FAK (Fig. 1 ). shLKB1 cells (supplemental Movie S3) appeared to show greater lamellipodia formation, with multiple lamellipodia protrusions sprouting in different directions at similar times. Furthermore, these shLKB1 cells appeared to have faster FAK site turnover (supplemental Movie S2) compared with control pLKO.1 cells (supplemental Movie S1); therefore, single-FAK site quantitative analysis was performed. The duration of individual GFP-FAK focal adhesion sites was 1295 Ϯ 111.2 s in pLKO.1 cells versus 456.0 Ϯ 68.0 s in shLKB1 cells (Fig. 6B) . Representative life plots of three focal adhesion sites in pLKO.1 cells and three sites in shLKB1 cells demonstrate that shLKB1 adhesion sites were shorter lived (Fig. 6C) . Furthermore, analysis of the initial 300 s of FAK site formation shows that FAK site size increased in control cells, whereas sites in shLKB1 cells showed no size maturation (Fig. 6D) . The overall mean size of individual focal adhesion sites was 1.5-fold smaller in shLKB1 cells compared with control pLKO.1 cells (Fig. 6E) . Taken together, these results show that LKB1 loss drives rapid focal adhesion site turnover.
DISCUSSION
LKB1 regulates numerous cellular functions including the AMPK energy-stress pathway (32) , cell cycle (44), chromatin remodeling (45), cytoskeletal reorganization (22) , cell polarization (23) , and cancer metastasis (37) . A genomic and proteomic screen in conditional LKB1
Ϫ/Ϫ mice in a k-ras mutant background showed increased activation of the FAK adhesion path- way (36) . Our results now show that loss of either LKB1 or its co-activator STRAD␣, enhances FAK phosphorylation at Tyr 397 and Tyr 861 , and also increases adhesion to fibronectin (Fig. 1) . It remains unclear if LKB1 loss enhances FAK phosphorylation at other sites, especially Tyr 576 , which is shown to be a major FAK phosphorylation site (47, 48) . Furthermore, re-expression of full-length LKB1 or domains containing the LKB1 NTD were capable of repressing FAK (Fig. 5) . The kinase domain alone was not capable of suppressing FAK suggesting that the NTD is a required region for this activity. These data suggest that wild-type LKB1 functions to repress FAK activation, whereby LKB1 loss results in enhanced FAK phosphorylation. This is further supported by the mutually exclusive accumulation of LKB1 and Tyr(P)-FAK at the cellular leading edge suggesting that the absence of LKB1 allows for FAK phosphorylation (Fig. 2, B and C) . Cumulatively, these data place LKB1 as a negative upstream regulator of FAK and adhesion signaling.
Importantly, LKB1 and total FAK are complexed together ( Fig. 2) and based upon an in vitro binding assay this association is not direct. LKB1 phosphorylates downstream AMPK family members (e.g. BRSKs and MARKs) and the interaction with FAK could be mediated by one of these substrates. Another interesting candidate is Nedd9, which associates with FAK (49), and LKB1 regulates its transcription through CRTC1 (50); however, this potential mechanism would suggest that LKB1 regulates FAK through control of Nedd9 transcription and not through a protein complex. We cannot exclude the possibility that LKB1 works through transcriptional regulation of FAK because it is possible that the nuclear localization of LKB1 is involved in FAK regulation; however, LKB1 does associate in a complex with total FAK (Fig. 2) and LKB1 does localize at the leading edge of cells (Fig. 2) , suggesting that the LKB1 represses FAK at the protein level.
Live-cell motility studies show that LKB1-compromised cells lack directional persistence and exhibit a more exploratory phenotype (Fig. 3) . FAK activation mediates this behavior because FAK inhibition through either pharmacological (Fig. 3 ) or molecular approaches (Fig. 4) restores directionality in LKB1-compromised cells. It was previously shown that FAK inactivation results in decreased directional persistence (51, 52) and here we show that FAK hyperactivation results in decreased directional persistence. In the previous cases, reduced cellular velocity was also observed, and therefore in these cells, motility is dampened. However, here, FAK hyperactivation in LKB1 shRNA cells results in no significant change in velocity indicating that cells move the same distance over time. Therefore, one can speculate that an imbalance of FAK activity levels (i.e. inactivation or hyperactivation) leads to reduced directional persistence but in the case of FAK inactivation, this is due to motility inhibition, whereas in the case of FAK hyperactivation, it is due to the rapid FAK turnover (Fig. 6) . Loss of directionality (or directional persistence) has been observed with other motility proteins. For instance, loss of the actinbinding protein Arp2/3 leads to poor directional persistence (53) and regulation of the small rhoGTPase pathway is necessary for proper cell polarization and directional persistence (54) . In fact, the observed increase in lamellipodia formation in LKB1 shRNA cells (supplemental Movie S3) has also been observed in other cases where cells exhibited poor directional persistence (55) .
The lack of directional persistence resulting from LKB1 loss is likely a result of rapid focal adhesion site turnover at the leading edge of motile cells. GFP-FAK sites in shLKB1 cells rapidly turnover and do not mature in size compared with control cells (Fig. 6 ). This observation is consistent with findings from immunofluorescence studies of Tyr(P) 397 -and Tyr(P) 861 -FAK sites, which again are smaller in size in shLKB1 cells compared with control cells (Fig. 1B) . One potential model is that when LKB1 function is compromised, FAK becomes hyperphosphorylated and focal adhesion sites in the growing lamellipodia exhibit rapid turnover. Indeed, FAK phosphorylation serves as a trigger for FAK cleavage (56, 57) , and therefore, the increased FAK phosphorylation observed is consistent with rapid FAK turnover.
Previous data link LKB1 to the cdc42 cell polarity pathway (22, 23) , and recently we have shown that STRAD␣ itself is linked to rac1-dependent polarity in an LKB1-independent role (43) . One possibility is that the loss of directionality and multiple lamellipodia protrusions (supplemental Movie S2) in LKB1-depleted cells could be due to aberrant rho GTPase signaling (55) . Interestingly, FAK signaling regulates cdc42 and rac1 activity, but the pathway is bidirectional whereby cdc42 and rac1 influence FAK phosphorylation as well (46) . The loss of directionality in LKB1 shRNA cells could therefore be due to lack of small rhoGTPase activity in these cells.
Taken together, these data support a model where LKB1 serves as a FAK repressor and complexes with FAK. When present, LKB1 stabilizes focal adhesions at the leading edge of migratory cells to repress focal adhesion site turnover, but when absent, FAK hyperphosphorylation ensues. It is unclear how the exploratory behavior observed upon LKB1 loss may impact cancer metastasis, but two possibilities are that it increases the likelihood of the cell contacting the ECM, or increases the probability of the cell locating a blood or lymphatic vessel to intravasate. Future studies will therefore go on to address how LKB1 loss impacts cell motility during cell invasion and can incorporate the use of novel knock-out models to study LKB1 function (24) .
